DiNuzzo Private Wealth Inc. Raises Stake in Thermo Fisher Scientific Inc. $TMO

DiNuzzo Private Wealth Inc. lifted its position in Thermo Fisher Scientific Inc. (NYSE:TMO) by 406.7% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 76 shares of the medical research company’s stock after acquiring an additional 61 shares during the quarter. DiNuzzo Private Wealth Inc.’s holdings in Thermo Fisher Scientific were worth $31,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently made changes to their positions in the company. Park Place Capital Corp raised its holdings in shares of Thermo Fisher Scientific by 52.1% in the second quarter. Park Place Capital Corp now owns 3,135 shares of the medical research company’s stock valued at $1,321,000 after acquiring an additional 1,074 shares in the last quarter. XML Financial LLC raised its holdings in shares of Thermo Fisher Scientific by 10.1% in the second quarter. XML Financial LLC now owns 1,056 shares of the medical research company’s stock valued at $428,000 after acquiring an additional 97 shares in the last quarter. Tealwood Asset Management Inc. raised its holdings in shares of Thermo Fisher Scientific by 33.7% in the second quarter. Tealwood Asset Management Inc. now owns 3,259 shares of the medical research company’s stock valued at $1,321,000 after acquiring an additional 821 shares in the last quarter. Asio Capital LLC raised its holdings in shares of Thermo Fisher Scientific by 2,088.1% in the second quarter. Asio Capital LLC now owns 11,969 shares of the medical research company’s stock valued at $4,853,000 after acquiring an additional 11,422 shares in the last quarter. Finally, Kavar Capital Partners Group LLC raised its holdings in shares of Thermo Fisher Scientific by 0.6% in the second quarter. Kavar Capital Partners Group LLC now owns 29,467 shares of the medical research company’s stock valued at $11,948,000 after acquiring an additional 162 shares in the last quarter. 89.23% of the stock is currently owned by institutional investors.

Insider Transactions at Thermo Fisher Scientific

In related news, EVP Gianluca Pettiti sold 400 shares of the stock in a transaction on Friday, July 25th. The stock was sold at an average price of $479.98, for a total value of $191,992.00. Following the completion of the transaction, the executive vice president directly owned 22,367 shares of the company’s stock, valued at approximately $10,735,712.66. This represents a 1.76% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CAO Joseph R. Holmes sold 385 shares of the stock in a transaction on Friday, August 29th. The shares were sold at an average price of $492.63, for a total value of $189,662.55. Following the completion of the transaction, the chief accounting officer directly owned 2,319 shares of the company’s stock, valued at approximately $1,142,408.97. This represents a 14.24% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 30,066 shares of company stock valued at $14,182,963 in the last three months. 0.33% of the stock is currently owned by company insiders.

Thermo Fisher Scientific Trading Down 0.5%

Shares of TMO stock opened at $461.95 on Tuesday. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.93 and a quick ratio of 1.50. The company has a market cap of $174.44 billion, a price-to-earnings ratio of 26.72, a PEG ratio of 2.52 and a beta of 0.75. The stock has a 50 day simple moving average of $477.84 and a 200-day simple moving average of $446.71. Thermo Fisher Scientific Inc. has a 1-year low of $385.46 and a 1-year high of $620.00.

Thermo Fisher Scientific (NYSE:TMO) last announced its earnings results on Wednesday, July 23rd. The medical research company reported $5.36 earnings per share for the quarter, topping the consensus estimate of $5.22 by $0.14. The business had revenue of $10.86 billion during the quarter, compared to the consensus estimate of $10.68 billion. Thermo Fisher Scientific had a return on equity of 16.82% and a net margin of 15.24%.The business’s quarterly revenue was up 2.9% on a year-over-year basis. During the same period in the prior year, the company posted $5.37 EPS. Thermo Fisher Scientific has set its Q3 2025 guidance at 5.460-5.510 EPS. FY 2025 guidance at 22.220-22.840 EPS. On average, equities research analysts expect that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current fiscal year.

Thermo Fisher Scientific Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, October 15th. Stockholders of record on Monday, September 15th will be paid a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a dividend yield of 0.4%. The ex-dividend date of this dividend is Monday, September 15th. Thermo Fisher Scientific’s dividend payout ratio is presently 9.95%.

Analyst Upgrades and Downgrades

Several research firms recently weighed in on TMO. William Blair began coverage on Thermo Fisher Scientific in a report on Monday, August 18th. They issued an “outperform” rating for the company. Raymond James Financial reiterated an “outperform” rating and issued a $535.00 target price (up previously from $525.00) on shares of Thermo Fisher Scientific in a research note on Thursday, July 24th. UBS Group lifted their target price on Thermo Fisher Scientific from $460.00 to $500.00 and gave the company a “neutral” rating in a research note on Thursday, July 24th. Royal Bank Of Canada set a $561.00 target price on Thermo Fisher Scientific and gave the company an “outperform” rating in a research note on Tuesday, September 2nd. Finally, HSBC reiterated a “hold” rating and issued a $510.00 target price on shares of Thermo Fisher Scientific in a research note on Thursday, July 24th. Sixteen research analysts have rated the stock with a Buy rating and five have given a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $588.35.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.